<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nogr</journal-id><journal-title-group><journal-title xml:lang="ru">Экспериментальная и клиническая гастроэнтерология</journal-title><trans-title-group xml:lang="en"><trans-title>Experimental and Clinical Gastroenterology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-8658</issn><publisher><publisher-name>«Global Media Technologies»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31146/1682-8658-ecg-206-10-63-69</article-id><article-id custom-type="elpub" pub-id-type="custom">nogr-2160</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНАЯ ГАСТРОЭНТЕРОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EXPERIMENTAL GASTROENTEROLOGY</subject></subj-group></article-categories><title-group><article-title>Клетки линии Сaco-2 как модель для изучения абсорбции лекарственных веществ</article-title><trans-title-group xml:lang="en"><trans-title>Cells of the Caco-2 line as a model for studying the absorption of medicinal substances</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1688-0017</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щулькин</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shchulkin</surname><given-names>A. V.</given-names></name></name-alternatives><email xlink:type="simple">alekseyshulkin@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5068-1201</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Транова</surname><given-names>Ю. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Tranova</surname><given-names>Yu. S.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0427-0967</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Абаленихина</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Abalenikhina</surname><given-names>Yu. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3984-8979</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Есенина</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Esenina</surname><given-names>A. S.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0696-6554</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Слепнев</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Slepnev</surname><given-names>A. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6887-4888</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Якушева</surname><given-names>Е. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Yakusheva</surname><given-names>E. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования Рязанский государственный медицинский университет имени академика И. П. Павлова Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ryazan State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>18</day><month>01</month><year>2023</year></pub-date><volume>0</volume><issue>10</issue><fpage>63</fpage><lpage>69</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Щулькин А.В., Транова Ю.С., Абаленихина Ю.В., Есенина А.С., Слепнев А.А., Якушева Е.Н., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Щулькин А.В., Транова Ю.С., Абаленихина Ю.В., Есенина А.С., Слепнев А.А., Якушева Е.Н.</copyright-holder><copyright-holder xml:lang="en">Shchulkin A.V., Tranova Y.S., Abalenikhina Y.V., Esenina A.S., Slepnev A.A., Yakusheva E.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.nogr.org/jour/article/view/2160">https://www.nogr.org/jour/article/view/2160</self-uri><abstract><p>Клетки линии Caco-2 обладают основными свойствами энтероцитов тонкого кишечника, а, следовательно, могут быть использованы для исследования абсорбции лекарственных веществ. Цель. Охарактеризовать и подтвердить свойства линии клеток Caco-2 из Института цитологии РАН и оценить с ее помощью механизм абсорбции оригинального отечественного лекарственного препарата - этилметилгидроксипиридина сукцината (ЭМГПС). Материалы и методы. Исследование выполнено на клетках Сасо-2, которые культивировали в течение 21 сут, так как при этом сроке происходит их спонтанная дифференцировка в поляризованные клетки, подобные энтероцитам тонкого кишечника. Плотность клеточного монослоя оценивали по величине трансэпителиального сопротивления. Количество основных эффлюксных белков транспортеров гликопротеина-Р (Pgp) и белка резистентности рака молочной железы (BCRP) в клетках Caco-2 анализировали с помощью иммуноферментного анализа. В специализированных трансвелл-системах изучали транспорт субстрата Pgp фексофенадина (40, 150 и 300 мкМ), субстрата BCRP - метотрексата (5, 10, 50 мкМ) и ЭМГПС (10, 100 и 250 мкМ) через клеточный монослой. Результаты исследования. К 21 сут культивирования клетки линии Сасо-2 формировали сливающийся монослой с плотными контактами. Количество Pgp и BCRP составило 110,8±14,1 нг/мг и 4,39±0,12 нг/мг соответственно, что соотносится с количеством данных белков в тонком кишечнике человека. Транспорт фексофенадина (40, 150 и 300 мкМ) и метотрексата (5 мкМ) из базолатеральной камеры в апикальную (соответствует транспорту из энтероцитов в просвет кишечника) преобладал над транспортом в противоположном направлении, что связано с функционированием Pgp и BCRP и подтверждает адекватность тест-системы. Транспорт ЭМГПС существенно превосходил по интенсивности транспорт фексофенадина и метотрексата и был симметричен по отношению к клеточному монослою. Заключение. Таким образом, клетки линии Caco-2, коммерчески доступные в Российской Федерации, обладают основными свойствами энтероцитов тонкого кишечника, и могут быть использованы для исследования абсорбции лекарственных веществ in vitro. ЭМГПС быстро проходит через клеточный монослой, а механизмом его абсорбции является пассивная диффузия, без участия специфических транспортеров - Pgp и BCRP.</p></abstract><trans-abstract xml:lang="en"><p>Cells of the Caco-2 line have the basic properties of enterocytes of the small intestine, and therefore can be used to study the absorption of medicinal substances. Aim. To characterize the properties of the Caco-2 cell line from the Institute of Cytology of the Russian Academy of Sciences and to evaluate with its help the mechanism of absorption of the original domestic drug - ethylmethylhydroxypyridine succinate (EMGPS). Materials and methods. The study was performed on Caco2 cells that were cultured for 21 days, since at this time their spontaneous differentiation into polarized cells similar to enterocytes of the small intestine occurs. The density of the cell monolayer was estimated by the value of transepithelial resistance. The number of major efflux proteins of glycoprotein-P transporters (Pgp) and breast cancer resistance protein (BCRP) in Caco-2 cells was analyzed using enzyme immunoassay. In specialized transwell systems, the transport of the Pgp substrate fexofenadine (40, 150 and 300 microns), the BCRP substrate methotrexate (5, 10, 50 microns) and EMGPS (10, 100 and 250 microns) through the cell monolayer was studied. The results of the study. By day 21 of cultivation, cells of the Caco2 line formed a merging monolayer with pronounced dense contacts. The amount of Pgp and BCRP was 110.8±14.1 ng/mg and 4.39±0.12 ng/mg, respectively, which correlates with the amount of these proteins in the human small intestine. Transport of fexofenadine (40, 150 and 300 microns) and methotrexate (5 microns) from the basolateral chamber to the apical chamber (corresponding to transport from enterocytes to the intestinal lumen) prevailed over transport in the opposite direction, which is associated with the work of Pgp and BCRP. The transport of EMGPS significantly exceeded the transport of fexofenadine and methotrexate and was symmetrical with respect to the cellular monolayer. Conclusion. Thus, the cells of the Caco-2 line, commercially available in the Russian Federation, have the basic properties of enterocytes of the small intestine, and can be used to study the absorption of medicinal substances in vitro. EMGPS quickly passes through the cellular monolayer, and the mechanism of its absorption is passive diffusion, without the participation of specific transporters.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>клетки линии Caco-2</kwd><kwd>абсорбция</kwd><kwd>гликопротеин-Р</kwd><kwd>белок резистентности рака молочной железы</kwd><kwd>этилметилгидроксипиридина сукцинат</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Caco-2 cells</kwd><kwd>absorption</kwd><kwd>glycoprotein-P</kwd><kwd>BCRP</kwd><kwd>ethylmethylhydroxypyridine succinate</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Fogh J., Fogh J. M., Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Nat Cancer Inst.1977; 59(1):221-226. doi: 10.1093/jnci/59.1.221.</mixed-citation><mixed-citation xml:lang="en">Fogh J., Fogh J. M., Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Nat Cancer Inst.1977; 59(1):221-226. doi: 10.1093/jnci/59.1.221.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Chantret I., Barbat A., Dusaulx E. et al. Epithelial polarity, vilin expresion, and enterocytic differentiation of cultured human colon carcinoma cels: A survey of twenty cell lines. Cancer Res.1988;48:1936.</mixed-citation><mixed-citation xml:lang="en">Chantret I., Barbat A., Dusaulx E. et al. Epithelial polarity, vilin expresion, and enterocytic differentiation of cultured human colon carcinoma cels: A survey of twenty cell lines. Cancer Res.1988;48:1936.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Sun H., Chow E. C., Liu S., et al. The Caco-2 cell monolayer: Usefulness and limitations. Expert Opin. Drug Metab. Toxicol. 2008;4(4): 395-411. doi: 10.1517/17425255.4.4.395.</mixed-citation><mixed-citation xml:lang="en">Sun H., Chow E. C., Liu S., et al. The Caco-2 cell monolayer: Usefulness and limitations. Expert Opin. Drug Metab. Toxicol. 2008;4(4): 395-411. doi: 10.1517/17425255.4.4.395.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Vachon P.H., Beaulieu J. F. Transient mosaic patterns of morphological and functional differentiation in the Caco-2 cell line. Gastroenterology. 1992; 103:414-423. doi: 10.1016/0016-5085(92)90829-n.</mixed-citation><mixed-citation xml:lang="en">Vachon P.H., Beaulieu J. F. Transient mosaic patterns of morphological and functional differentiation in the Caco-2 cell line. Gastroenterology. 1992; 103:414-423. doi: 10.1016/0016-5085(92)90829-n.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Watson C.J., Rowland M., Warhurst G. Functional modeling of tight junctions in intestinal cell monolayers using polyethylene glycol oligomers. Am J Physiol Cell Physiol. 2001;281:388-397. doi: 10.1152/ajpcell.2001.281.2.C388.</mixed-citation><mixed-citation xml:lang="en">Watson C.J., Rowland M., Warhurst G. Functional modeling of tight junctions in intestinal cell monolayers using polyethylene glycol oligomers. Am J Physiol Cell Physiol. 2001;281:388-397. doi: 10.1152/ajpcell.2001.281.2.C388.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Thambavita D., Galappatthy P., Mannapperuma U., et al. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Amoxicillin Trihydrate. J Pharm Sci. 2017;106(10):2930-2945. doi: 10.1016/j.xphs.2017.04.068.</mixed-citation><mixed-citation xml:lang="en">Thambavita D., Galappatthy P., Mannapperuma U., et al. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Amoxicillin Trihydrate. J Pharm Sci. 2017;106(10):2930-2945. doi: 10.1016/j.xphs.2017.04.068.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Tampal N., Mandula H., Zhang H., et al. Biopharmaceutics classification system-based biowaivers for generic oncology drug products: case studies. AAPS PharmSciTech. 2015;16(1):5-9. doi: 10.1208/s12249-014-0195-7.</mixed-citation><mixed-citation xml:lang="en">Tampal N., Mandula H., Zhang H., et al. Biopharmaceutics classification system-based biowaivers for generic oncology drug products: case studies. AAPS PharmSciTech. 2015;16(1):5-9. doi: 10.1208/s12249-014-0195-7.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER). In Vitro Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter Mediated Drug Interactions Guidance for Industry, 2020, 43 P.</mixed-citation><mixed-citation xml:lang="en">U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER). In Vitro Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter Mediated Drug Interactions Guidance for Industry, 2020, 43 P.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Liu X., Pan G. Drug Transporters in Drug Disposition, Effects and Toxicity. Advances in Experimental Medicine and Biology. 2019; 1141:580 P.</mixed-citation><mixed-citation xml:lang="en">Liu X., Pan G. Drug Transporters in Drug Disposition, Effects and Toxicity. Advances in Experimental Medicine and Biology. 2019; 1141:580 P.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Natoli M., Leoni B. D., D’Agnano I., Zucco F., Felsani A. Good Caco-2 cell culture practices. Toxicol In Vitro. 2012. 26(8):1243-6. doi:10.1016/j.tiv.2012.03.009.</mixed-citation><mixed-citation xml:lang="en">Natoli M., Leoni B. D., D’Agnano I., Zucco F., Felsani A. Good Caco-2 cell culture practices. Toxicol In Vitro. 2012. 26(8):1243-6. doi:10.1016/j.tiv.2012.03.009.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Elsby R., Surry D. D., Smith V. N., Gray A. J. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotic. 2008;(38):1140-1164. doi:10.1080/00498250802050880.</mixed-citation><mixed-citation xml:lang="en">Elsby R., Surry D. D., Smith V. N., Gray A. J. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotic. 2008;(38):1140-1164. doi:10.1080/00498250802050880.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Erokhina P.D., Abalenikhina Yu.V., Shchulkin A. V., Chernykh I. V. et al. A study of influence of progesterone on activity of glycoprotein-P in vitro. I. P. Pavlov Russian Medical Biological Herald. 2020;28(2):135-42. (in Russ.) doi:10.23888/PAVLOVJ2020282135-142.@@ Ерохина П. Д., Абаленихина Ю. В., Щулькин А. В., Черных И. В. и др. Изучение влияния прогестерона на активность гликопротеина-Р in vitro. Российский медико-биологический вестник имени академика И. П. Павлова. 2020; 28(2): 135-142. doi:10.23888/PAVLOVJ2020282135-142.</mixed-citation><mixed-citation xml:lang="en">Erokhina P.D., Abalenikhina Yu.V., Shchulkin A. V., Chernykh I. V. et al. A study of influence of progesterone on activity of glycoprotein-P in vitro. I. P. Pavlov Russian Medical Biological Herald. 2020;28(2):135-42. (in Russ.) doi:10.23888/PAVLOVJ2020282135-142.@@ Ерохина П. Д., Абаленихина Ю. В., Щулькин А. В., Черных И. В. и др. Изучение влияния прогестерона на активность гликопротеина-Р in vitro. Российский медико-биологический вестник имени академика И. П. Павлова. 2020; 28(2): 135-142. doi:10.23888/PAVLOVJ2020282135-142.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Chernyh I.V., SHCHul’kin A.V., Gacanoga M. V., Myl’nikov P.YU. [Development of an HPLC method for the quantitative determination of ethylmethylhydroxypyridine succinate in the blood plasma of rats and rabbits]. I. P. Pavlov Russian Medical Biological Herald. 2015;23(1):62-66. (In Russ).@@ Черных И. В., Щулькин А. В., Гацанога М. В., Мыльников П. Ю. Разработка ВЭЖХ методики количественного определения этилметилгидроксипиридина сукцината в плазме крови крыс и кроликов. Российский медико-биологический вестник имени академика И. П. Павлова. 2015;(23)1:62-66.</mixed-citation><mixed-citation xml:lang="en">Chernyh I.V., SHCHul’kin A.V., Gacanoga M. V., Myl’nikov P.YU. [Development of an HPLC method for the quantitative determination of ethylmethylhydroxypyridine succinate in the blood plasma of rats and rabbits]. I. P. Pavlov Russian Medical Biological Herald. 2015;23(1):62-66. (In Russ).@@ Черных И. В., Щулькин А. В., Гацанога М. В., Мыльников П. Ю. Разработка ВЭЖХ методики количественного определения этилметилгидроксипиридина сукцината в плазме крови крыс и кроликов. Российский медико-биологический вестник имени академика И. П. Павлова. 2015;(23)1:62-66.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Mylnikov P. Yu., Tranova Yu., Shchulkin A. V., Yakusheva E. N. Development and validation of the method for the quantitative determination of methotrexate in a transport medium by HPLC-MS/MS. Pharmacokinetics and Pharmacodynamics. 2021;(1):45-51. (In Russ.) doi:10.37489/2587-7836-2021-1-45-51.@@ Мыльников П. Ю., Транова Ю., Щулькин А. В., Якушева Е. Н. Разработка и валидация методики количественного определения метотрексата в транспортной среде методом ВЭЖХ-МC/МС. Фармакокинетика и фармакодинамика. 2021;(1):45-51. doi:10.37489/2587-7836-2021-1-45-51.</mixed-citation><mixed-citation xml:lang="en">Mylnikov P. Yu., Tranova Yu., Shchulkin A. V., Yakusheva E. N. Development and validation of the method for the quantitative determination of methotrexate in a transport medium by HPLC-MS/MS. Pharmacokinetics and Pharmacodynamics. 2021;(1):45-51. (In Russ.) doi:10.37489/2587-7836-2021-1-45-51.@@ Мыльников П. Ю., Транова Ю., Щулькин А. В., Якушева Е. Н. Разработка и валидация методики количественного определения метотрексата в транспортной среде методом ВЭЖХ-МC/МС. Фармакокинетика и фармакодинамика. 2021;(1):45-51. doi:10.37489/2587-7836-2021-1-45-51.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Department of Health and Human Services, Food and Drug Administration, Center for Drug Evolution and Research (CDER). Bioanalytical method validation. U. S. Government Printing Office: Washington, DC, 2018, 41 P.</mixed-citation><mixed-citation xml:lang="en">Department of Health and Human Services, Food and Drug Administration, Center for Drug Evolution and Research (CDER). Bioanalytical method validation. U. S. Government Printing Office: Washington, DC, 2018, 41 P.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kim K.A., Park J. Y. Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers. Eur J Clin Pharmacol. 2010; 66(7):721-5. doi: 10.1007/s00228-010-0797-2.</mixed-citation><mixed-citation xml:lang="en">Kim K.A., Park J. Y. Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers. Eur J Clin Pharmacol. 2010; 66(7):721-5. doi: 10.1007/s00228-010-0797-2.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Hilgers A.R., Conradi R. A., Burton P. S. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm Res. 1990;(7):902-910. doi:10.1023/a:1015937605100</mixed-citation><mixed-citation xml:lang="en">Hilgers A.R., Conradi R. A., Burton P. S. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm Res. 1990;(7):902-910. doi:10.1023/a:1015937605100</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Fine K.D., Santa Ana C. A., Porter J. L., Fordtran J. S. Effect of changing intestinal flow rate on a measurement of intestinal permeability. Gastroenterology. 1995;108:983-989. doi: 10.1016/0016-5085(95)90193-0.</mixed-citation><mixed-citation xml:lang="en">Fine K.D., Santa Ana C. A., Porter J. L., Fordtran J. S. Effect of changing intestinal flow rate on a measurement of intestinal permeability. Gastroenterology. 1995;108:983-989. doi: 10.1016/0016-5085(95)90193-0.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Majdoub Z.M., Achour B., Couto N., Howard M., Elmorsi Y. et al. Mass spectrometry-based abundance atlas of ABC transporters in human liver, gut, kidney, brain and skin. FEBS Lett. 2020;594(23):4134-4150. doi: 10.1002/1873-3468.13982.</mixed-citation><mixed-citation xml:lang="en">Al-Majdoub Z.M., Achour B., Couto N., Howard M., Elmorsi Y. et al. Mass spectrometry-based abundance atlas of ABC transporters in human liver, gut, kidney, brain and skin. FEBS Lett. 2020;594(23):4134-4150. doi: 10.1002/1873-3468.13982.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Maksimovic V., Pavlovic-Popovic Z., Vukmirovic S., Cvejic J. et al. Molecular mechanism of action and pharmacokinetic properties of methotrexate. Mol Biol Rep. 2020;47(6):4699-4708. doi: 10.1007/s11033-020-05481-9</mixed-citation><mixed-citation xml:lang="en">Maksimovic V., Pavlovic-Popovic Z., Vukmirovic S., Cvejic J. et al. Molecular mechanism of action and pharmacokinetic properties of methotrexate. Mol Biol Rep. 2020;47(6):4699-4708. doi: 10.1007/s11033-020-05481-9</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Narawa T., Tsuda Ya., Itoh T. Chiral Recognition of Amethopterin Enantiomers by the Reduced Folate Carrier in Caco-2 Cells. Drug Metab. Pharmacokinet. 2007;22(1):33-40. doi: 10.2133/dmpk.22.33.</mixed-citation><mixed-citation xml:lang="en">Narawa T., Tsuda Ya., Itoh T. Chiral Recognition of Amethopterin Enantiomers by the Reduced Folate Carrier in Caco-2 Cells. Drug Metab. Pharmacokinet. 2007;22(1):33-40. doi: 10.2133/dmpk.22.33.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Shchul’kin A.V., CHernyh I.V., Gacanoga M. V., YAkusheva E. N. Vliyanie afobazola na aktivnost’ ABCB1-belka u pacientov s nizkoj trevozhnost’yu. [Effect of afobazole on ABCB1 protein activity in patients with low anxiety]. Pharmacogenetics and Pharmacogenomics. 2019;(2):35-37. (In Russ.) doi: 10.24411/2588-0527-2019-10060.@@ Щулькин А. В., Черных И. В., Гацанога М. В., Якушева Е. Н. Влияние афобазола на активность ABCB1-белка у пациентов с низкой тревожностью. Фармакогенетика и фармакогеномика. 2019;2:35-37. doi: 10.24411/2588-0527-2019-10060. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Shchul’kin A.V., CHernyh I.V., Gacanoga M. V., YAkusheva E. N. Vliyanie afobazola na aktivnost’ ABCB1-belka u pacientov s nizkoj trevozhnost’yu. [Effect of afobazole on ABCB1 protein activity in patients with low anxiety]. Pharmacogenetics and Pharmacogenomics. 2019;(2):35-37. (In Russ.) doi: 10.24411/2588-0527-2019-10060.@@ Щулькин А. В., Черных И. В., Гацанога М. В., Якушева Е. Н. Влияние афобазола на активность ABCB1-белка у пациентов с низкой тревожностью. Фармакогенетика и фармакогеномика. 2019;2:35-37. doi: 10.24411/2588-0527-2019-10060. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Shchulkin A.V., Yakusheva E. N., Chernykh I. V. The distribution of mexidol in the rat’s brain and its subcellular fractions. Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova. 2014;114(8):70-73. (In Russ.)@@ Щулькин А. В., Якушева Е. Н., Черных И. В. Распределение мексидола в структурах головного мозга, его клеточных элементах и субклеточных фракциях. Журнал неврологии и психиатрии им. С. С. Корсакова. 2014;114(8):70-73.</mixed-citation><mixed-citation xml:lang="en">Shchulkin A.V., Yakusheva E. N., Chernykh I. V. The distribution of mexidol in the rat’s brain and its subcellular fractions. Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova. 2014;114(8):70-73. (In Russ.)@@ Щулькин А. В., Якушева Е. Н., Черных И. В. Распределение мексидола в структурах головного мозга, его клеточных элементах и субклеточных фракциях. Журнал неврологии и психиатрии им. С. С. Корсакова. 2014;114(8):70-73.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
